Malaria vaccine development: Current status

Parasitology Today

Volumn 14, Issue 2, 1998, Pages 56-64

  Engers, Howard D ^a   Godal, Tore ^a  

^a WORLD BANK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

DRUG TARGETING; HUMAN; IMMUNOGENICITY; MALARIA; MEDICAL RESEARCH; MEROZOITE; NONHUMAN; REVIEW; SPOROZOITE;

EID: 0032008130     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(97)01184-8     Document Type: Review

References (64)

1. 1 WHO (1997) World Malaria Situation in 1994. Weekly Epidemiological Record, WHO
2. 2 WHO (1996) Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development (TDR/Gen/96.1), WHO
3. 3 WHO (1996) Malaria Control Among Refugees and Displaced Populations (CTD/MAL/96.6), WHO
4. 4 WHO (1993) A Global Strategy for Malaria Control, WHO
5. 5 IOM (1991) in Malaria: Obstacles and Opportunities. A report of the Division of International Health, Institute of Medicine (Oaks, S.C., Jr, ed.), pp 211-236, National Academy Press
6. 6 WHO/World Bank (1996) Operational Issues in Malaria Control Report of a Working Meeting, Airlie, Virginia, USA, September 1995, WHO
7. 7 Olliaro, P. and Trigg, P.I. (1995) Status of antimalarial drugs under development. Bull. WHO 73, 565-571
8. 8 Martens, J.M. et al. (1995) Potential impact of global change on malaria risk. Environ. Health Perspect. 103, 458-464
9. 9 Marsh, K. (1992) Malaria - a neglected disease? Parasitology 104, S53-S69
10. 10 Miller, L.H., Good, M.F. and Kaslow, D.C. (1997) The need for assays predictive of protection in development of malarial blood stage vaccines. Parasitol. Today 13, 46-47
11. 11 Kaslow, D.C. (1997) in New Generation Vaccines (Levine, M.M. et al., eds), pp 1057-1063, Marcel Dekker
12. 12 Nussenzweig, R.S. et al. (1967) Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162
13. 13 Clyde, D.F. et al. (1973) Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 169-177
14. 14 Trager, W. and Jensen, J.B. (1976) Human malaria parasites in continuous culture. Science 193, 673-675
15. 15 Ponnudurai, T. et al. (1982) Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. Trans. R. Soc. Trop. Med. Hyg. 76, 812-818
16. 16 Waters, A. et al. (1996) Transfection of malaria parasites. Parasitol. Today 12, 129-132
17. 17 Holder, A.A. (1996) in Malaria Vaccine Development: A Multi-immune Response Approach (Hoffman, S.L., ed.), pp 181-227, ASM Press
18. 18 Crewther, P.E. et al. (1996) Protective immune responses to the apical membrane antigen 1 (AMA-1) of P. chabaudi recognise strain-specific epitopes. Infect. Immun. 64, 3310-3317
19. 19 Inselburg, J. et al. (1993) Protective immunity is induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect. Immun. 61, 2048-2052
20. 20 Young, R.A. and Davis, R.W. (1983) Efficient isolation of genes using antibody probes. Proc. Natl. Acad. Sci. U. S. A. 80, 1194-1198
21. 21 Hoffman, S.L., ed. (1996) Malaria Vaccine Development: A Multi-immune Response Approach, ASM Press
22. 22 Amador, R. and Patarroyo, M.E. (1997) in New Generation Vaccines (Levine, M.M. et al., eds), pp 1027-1033, Marcel Dekker
23. 23 Ramasamy, R. et al. (1995) Antibody and clinical responses in volunteers to immunization with malaria peptide-diphtheria toxoid conjugates. Clin. Exp. Immunol. 99, 168-174
24. 24 de-Oliveira, G.A. et al. (1994) Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B-and T-cell epitopes of the P. falciparum CS protein: possible vaccine application. Vaccine 12, 1012-1017
25. 25 Wang, R. et al. (1995) Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 154, 2784-2793
26. 26 Doolan, D. and Hoffman, S.L. (1997) Multi-gene vaccination against malaria: a multistage, multi-immune response approach. Parasitol. Today 13, 171-178
27. 27 Gordon, D.M. (1993) Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine 11, 591-593
28. 28 Gupta, R.K. and Siber, G.R. (1995) Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13, 1263-1276
29. 29 Fries, L.F. et al. (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U. S. A. 89, 358-362
30. 30 Brown, A.E. et al. (1994) Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 12, 102-108
31. 31 Hoffman, S.L. et al. (1994) Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg. 51, 603-612
32. 32 Ott, G., Barchfeld, G.L. and Van-Nest, G. (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13, 1557-1562
33. 33 Gordon, D.M. et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576-1585
34. 34 Stoute, J.A. et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. New Engl. J. Med. 336, 86-91
35. 35 Livingston, P.O. (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147-166
36. 36 Lawrence, G.W. (1997) Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15, 176-178
37. 37 Lord, R. et al. (1993) Mice immunized with a synthetic peptide construct corresponding to an epitope present on a Plasmodium falciparum antigen are protected against Plasmodium chabaudi challenge. Parasite Immunol. 15, 613-618
38. 38 Chatterjee, S. et al. (1994) A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect. Immun. 63, 4375-4381
39. 39 Ballou, W.R. et al. (1987) Safety and efficacy of a recombinant DNA Plasmodium falciparum vaccine. Lancet i, 1277-1281
40. 40 Herrington, D.A. et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257-259
41. 41 Sturchler, D. et al. (1992) Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults. Trop. Geogr. Med. 44, 9-14
42. 42 Reber-Liske, R. et al. (1995) [NANP]19-5.1. A malaria vaccine field trial in Nigerian children. Trop. Geogr. Med. 47, 61-63
43. 43 Sturchler, D. et al. (1995) Safety, immunogenicity and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am. J. Trop. Med. Hyg. 53, 423-431
44. 44 Patarroyo, M.E. et al. (1987) Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328, 629-632
45. 45 Patarroyo, M.E. et al. (1988) A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158-161
46. 46 D'Alessandro, U. et al. (1995) Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346, 462-467
47. 47 Ballou, W.R. et al. (1995) Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study. Parasitology 110, S25-S36
48. 48 Nosten, F. et al. (1996) Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. SHOKLO SPf66 Malaria Vaccine Trial Group. Lancet 348, 701-707
49. 49 Graves, P. (1997) The Cochrane Database of Systematic Reviews, Issue 1 (Garner, P., Gelband, H. and Salinas, R., eds), The Cochrane Library
50. 50 WHO (1996) Guidelines for the Evaluation of Plasmodium falciparum Vaccines in Populations Exposed to Natural Infection (Document TDR/PF/VAC/96), WHO
51. 51 Blackman, M.J. et al. (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172, 379-382
52. 52 Daly, T.M. and Long, C.A. (1993) A recombinant 15-kilodalton carboxy-terminal fragment of Plasmodium yoelii 17XL merozoite surface protein-1 induces a protective response in mice. Infect. Immun. 61, 2462-2467
53. 53 Chappel, J.A. and Holder, A.A. (1993) Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60, 303-312
54. 54 Tine, J.A. et al. (1996) NYVAC-Pf7: a poxvirus-vectored, multi-antigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64, 3833-3844
55. 55 Gorse, G.J. et al. (1994) Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. (NIAID AIDS Vaccine Clinical Trials Network.) Vaccine 12, 912-918
56. 56 Su, X.Z. et al. (1995) The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82, 89-100
57. 57 Baruch, D.I. et al. (1995) Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82, 77-87
58. 58 Good, M.F., Saul, A. and Graves, P.M. (1992) Malaria vaccines. Biotechnology 20, 69-98
59. 59 Van Regenmortel, M. (1995) Transcending the structuralist paradigm in immunology - affinity and biology activity rather than purely structural considerations should guide the design of synthetic peptide epitopes. Biomed. Peptides Proteins Nucleic Acids 1, 109-116
60. 60 PRISM (1996) Malaria Research: an Audit of International Activity. PRISM Report Number 7. Wellcome Trust
61. 61 AMVTN (1995) Proceedings of the First African Malaria Vaccine Testing Network Meeting, Arusha, Tanzania
62. 62 WHO (1986) Guidelines for the Epidemiological Evaluation of Plasmodium falciparum sporozoite vaccines (Document TDR/ MAP/SVE/PF/86.5), WHO
63. 63 WHO (1989) Guidelines for the Evaluation of Plasmodium falciparum Asexual Blood-stage Vaccines in Populations Exposed to Natural Infection (Doc. TDR/MAP/SVE/PF/89.5), WHO
64. 64 WHO (1992) Guidelines for Community-based Trials of Vaccines Against the Sexual Stages of Malaria Parasites (Document TDR/ CTD/TBV/92), WHO